Table 2 Univariate and multivariate analysis of baseline risk factors associated with grade 2 or more ALT elevation
Odds ratio | 95 % CI | p value | |
|---|---|---|---|
Univariate analysis | |||
Raltegravir vs enfuvirtide | 1.66 | (0.61–4.51) | 0.322 |
Age (↑ 10 years) | 1.12 | (0.62–2.05) | 0.702 |
Sex (female/male) | 2.36 | (0.76–7.31) | 0.136 |
Body mass index (BMI) (↑ 5) | 0.73 | (0.31–1.70) | 0.469 |
CD4 cell count (↑ 100 cells/µL) | 1.08 | (0.87–1.34) | 0.502 |
ART duration (↑ 1 year) | 0.86 | (0.70–1.05) | 0.149 |
History of drug abuse | 0.92 | (0.11–7.73) | 0.940 |
Use of boosted tipranavir at baseline | 3.56 | (1.26–10.0) | 0.016 |
ALT elevation (grade 1 or more) | 8.78 | (2.80–27.6) | <10−3 |
Alcohol use (>2 times/week) | 0.54 | (0.12–2.51) | 0.435 |
Hepatitis B or C co-infection | 0.82 | (0.10–6.84) | 0.857 |
Liver disease at baseline (steatosis/cirrhosis) | 2.53 | (0.63–10.1) | 0.189 |
Use of lipid lowering agents | 2.06 | (0.76–5.57) | 0.156 |
Multivariate analysis | |||
Use of boosted tipranavir | 3.66 | (1.20–11.1) | 0.022 |
ALT elevation (grade 1 or more) | 10.3 | (2.67–39.6) | <10−3 |
Alcohol use (>2 times/week) | 0.39 | (0.07–2.16) | 0.281 |
Liver disease at baseline (steatosis/cirrhosis) | 0.89 | (0.16–5.01) | 0.899 |